undamentalytics Newsletter
Sign in

Neuronetics, Inc. revenue

Neuronetics, Inc.'s revenue was $149m in fiscal 2025, up 99.2% on the year before. Since fiscal 2016 ($34.2m) it has grown at a compound 17.8% a year. Over the last twelve months it was $155m.

Revenue history

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue344053634955657175149155
Growth on the year before—+18.1%+30.5%+18.7%−21.4%+12.3%+17.9%+9.4%+5.0%+99.2%—
Gross profit2831404738445052547276
Gross margin80.7%76.2%76.4%75.4%76.5%78.9%76.3%72.5%72.3%48.5%49.1%

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Where the revenue comes from

Fiscal year to December 31, 2025
Segments
Line of business Revenue Share YoY
Clinical Services $87M 58.3% ▲ 1856.7%
Medical Device $62.2M 41.7% ▼ 11.7%
Products and services
Line of business Revenue Share YoY
Services $87M 58.3% ▲ 1856.7%
Products $62.2M 41.7% ▼ 11.7%

From Neuronetics, Inc.'s 10-K filed March 17, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Revenue against peers

Health Care Equipment: the closest covered companies by revenue. Last twelve months.

CompanyRevenueGrowth3-year growth a year
Neuronetics, Inc. $155m 39.6% 31.7%
Infusystem Holdings, Inc $143m 2.5% 6.6%
Rxsight, Inc. $128m -13.2% 23.9%
Beta Bionics, Inc. $127m 43.7% —
Lakeland Industries Inc $191m -0.3% 17.0%
Anika Therapeutics, Inc. $121m 5.3% 0.3%

Compare with peers

Head to head: INFU vs STIMRXST vs STIMBBNX vs STIMLAKE vs STIM

More: Health Care Equipment stocks compared, Health Care sector, rankings of US companies

Figures from Neuronetics, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Neuronetics, Inc.